Jazz Pharmaceuticals (JAZZ) Jefferies Global Healthcare Conference 2026 summary

Strategic evolution and R&D expansion

• Transitioned from a narrow sleep drug focus to a diversified biopharma with strong oncology and neuroscience franchises, leveraging acquisitions and internal innovation.

• Developed and expanded key products like XYWAV, Rylaze, ZEPZELCA, and zanidatamab, with successful label extensions and new indications.

• Built a robust epilepsy portfolio post-GW Pharmaceuticals acquisition, including in-house discovery efforts for absence epilepsy.

• Demonstrated rapid execution from data readout to regulatory submission, notably with HERIZON-GEA-01.

• Positioned as a partner of choice for future deals and collaborations in rare diseases and oncology.

Pipeline and clinical development highlights

• Zanidatamab demonstrated superiority over HERCEPTIN in frontline GEA, with robust survival data and potential for broad label approval.

• Ongoing and planned studies target adjuvant, neoadjuvant, and post-ENHERTU settings in breast and gastric cancers, aiming to expand market opportunities.

• Phase III trials in refractory post-ENHERTU breast cancer and combinations with next-generation HER2 TKIs are underway, with confidence in success based on biology and early data.

• Basket trials are designed for tumor-agnostic indications and potential accelerated approvals in specific tumor types.

• Internal orexin program continues, with a focus on differentiated PK profiles for broader CNS indications.

Regulatory and commercial momentum

• Achieved rapid regulatory progress for zanidatamab, including breakthrough designation, priority review, and NCCN engagement.

• Confident in demonstrating overall survival benefit in upcoming interim analyses, with mechanisms for rapid label updates.

• Strong physician enthusiasm and formulary presence in BTC and GEA support anticipated uptake.

• Open to strategic partnerships for broader development and commercialization, with ongoing discussions and inbound interest.

• Basket trial strategy aligns with FDA expectations for registrational and signal-finding purposes.